The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: Emphasis on non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 824-833

  Bremnes, Roy M ^a,b   Al Shibli, Khalid ^a,c   Donnem, Tom ^a,b   Sirera, Rafael ^d   Al Saad, Samer ^a,b   Andersen, Sigve ^a,b   Stenvold, Helge ^a,b   Camps, Carlos ^e   Busund, Lill Tove ^a,e  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

^d UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Immune cells; In situ immunology; Lung cancer; NSCLC; Stroma; Tumor; Tumor microenvironment

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MACROPHAGE; MAST CELL; METASTASIS; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TUMOR LOCALIZATION;

EID: 79953028602     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182037b76     Document Type: Review

References (149)

1. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6: 392-401.
2. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37. (Pubitemid 43053650)
3. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-252.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. (Pubitemid 32173595)
5. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
6. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217. (Pubitemid 40568680)
7. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-3044.
8. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-444.
9. De Visser KE, Coussens LM. The interplay between innate and adap-tive immunity regulates cancer development. Cancer Immunol Immu-nother 2005;54:1143-1152. (Pubitemid 41396818)
10. Allavena P, Sica A, Solinas G, et al. The inflammatory micro-environ-ment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008;66:1-9. (Pubitemid 351324128)
11. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-346. (Pubitemid 41443435)
12. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964. (Pubitemid 41746764)
13. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
14. Walzer T, Jaeger S, Chaix J, et al. Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Im-munol 2007;19:365-372. (Pubitemid 46687010)
15. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol 2004;4:190-198. (Pubitemid 38339085)
16. Casetti R, Martino A. The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 2008;5:161-170.
17. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202:203-207. (Pubitemid 41043815)
18. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999;402:255-262. (Pubitemid 129516254)
19. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302:575-581.
20. McHeyzer-Williams MG. B cells as effectors. Curr Opin Immunol 2003;15:354-361. (Pubitemid 36645115)
21. Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002;20:551-579. (Pubitemid 34293434)
22. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-124. (Pubitemid 40208901)
23. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005;17:29-35. (Pubitemid 40094010)
24. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004;5:996-1002. (Pubitemid 41057716)
25. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-974. (Pubitemid 41057712)
26. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361. (Pubitemid 40852711)
27. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756-4760. (Pubitemid 32691887)
28. Ostrand-Rosenberg S. Immune surveillance: a balance between protu-mor and antitumor immunity. Curr Opin Genet Dev 2008;18:11-18. (Pubitemid 351694442)
29. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 2007;28: 491-496. (Pubitemid 350087811)
30. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27:3889-3900. (Pubitemid 351913639)
31. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998. (Pubitemid 35363648)
32. Carosella ED, Favier B, Rouas-Freiss N, et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111:4862-4870.
33. Yie SM, Yang H, Ye SR, et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007;58:267-274. (Pubitemid 47516690)
34. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-867. (Pubitemid 36019639)
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
36. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveil-lance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727. (Pubitemid 44453458)
37. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36-37.
38. Pages F, Galon J, eu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-1102.
39. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-4417.
40. Gould SJ, Isaacson PG. Bronchus-associated lymphoid tissue (BALT) in human fetal and infant lung. J Pathol 1993;169:229-234. (Pubitemid 23063461)
41. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Patho-biology 2000;68:1-8. (Pubitemid 30434161)
42. Esposito I, Menicagli M, Funel N, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004;57:630-636. (Pubitemid 38725766)
43. Yano H, Kinuta M, Tateishi H, et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 1999;2:26-32.
44. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423. (Pubitemid 40719125)
45. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogen-esis. Genes Dev 1999;13:1382-1397. (Pubitemid 29270244)
46. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6: 447-458. (Pubitemid 39469981)
47. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. JClin Invest 2007;117:1155-1166. (Pubitemid 46718400)
48. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475. (Pubitemid 350007692)
49. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haema-topoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827. (Pubitemid 41753060)
50. Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450:825-831. (Pubitemid 350231321)
51. Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived sup-pressor cells and limits tumor progression. Cancer Res 2007;67: 10019-10026. (Pubitemid 47621253)
52. Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103:481-490.
53. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-740.
54. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-270.
55. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007;26:373-400. (Pubitemid 350115102)
56. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated mac-rophages in tumour progression: implications for new anticancer ther-apies. JPathol 2002;196:254-265. (Pubitemid 34189413)
57. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-631.
58. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-5802.
59. Soucek L, Lawlor ER, Soto D, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-1218. (Pubitemid 47530639)
60. Ribatti D, Crivellato E, Roccaro AM, et al. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004;34: 1660-1664. (Pubitemid 39551516)
61. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoi-etic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-226. (Pubitemid 41317592)
62. Venneri MA, De PM, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109:5276-5285. (Pubitemid 46890548)
63. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mono-nuclear phagocytes. Trends Immunol 2002;23:549-555. (Pubitemid 35223554)
64. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35. (Pubitemid 37328697)
65. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Im-munol 2004;25:677-686. (Pubitemid 39457982)
66. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-969.
67. Pollard JW. Tumour-educated macrophages promote tumour progres-sion and metastasis. Nat Rev Cancer 2004;4:71-78. (Pubitemid 38082155)
68. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266. (Pubitemid 43121975)
69. Serafini P, De SC, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53: 64-72. (Pubitemid 38161211)
70. Gabrilovich DI, Velders MP, Sotomayor EM, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001;166:5398-5406. (Pubitemid 32374159)
71. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
72. Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15:730-738. (Pubitemid 351627356)
73. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449: 557-563. (Pubitemid 47525152)
74. Lodie TA, Blickarz CE, Devarakonda TJ, et al. Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction. Tissue Eng 2002;8:739-751. (Pubitemid 35239752)
75. Al-Shibli K, Al-Saad S, Donnem T, et al. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009;55:301-312.
76. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macro-phages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008;113:1387-1395.
77. Welsh TJ, Green RH, Richardson D, et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23:8959-8967. (Pubitemid 46211481)
78. Ma J, Liu L, Che G, et al. The M1 form of tumor-associated macro-phages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010;10:112.
79. Ohri CM, Shikotra A, Green RH, et al. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associ-ated with extended survival. Eur Respir J2009;33:118-126.
80. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-5943.
81. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008;9:503-510. (Pubitemid 351560519)
82. Smyth MJ, Godfrey DI. NKT cells and tumor immunity\a double-edged sword. Nat Immunol 2000;1:459-460.
83. Papamichail M, Perez SA, Gritzapis AD, et al. Natural killer lympho-cytes: biology, development, and function. Cancer Immunol Immu-nother 2004;53:176-186. (Pubitemid 38328040)
84. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520.
85. Moodycliffe AM, Nghiem D, Clydesdale G, et al. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000;1:521-525.
86. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008;69:811-814.
87. Janeway C, Travers P, Walport M, et al. Immunobiology\the immune system in health and disease. New York: Garland Science Publishing, 2005.
88. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006;177:896-904. (Pubitemid 44036590)
89. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274. (Pubitemid 40488632)
90. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-6958. (Pubitemid 350276874)
91. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195:695-704. (Pubitemid 34259715)
92. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735)
93. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276. (Pubitemid 34441324)
94. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-5380. (Pubitemid 46623168)
95. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carci-noma after resection. J Clin Oncol 2007;25:2586-2593. (Pubitemid 47041232)
96. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
97. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133. (Pubitemid 29316012)
98. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2002;2:265-278. (Pubitemid 34464808)
99. Kataki A, Scheid P, Piet M, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140: 320-328. (Pubitemid 35302024)
100. Ishibashi Y, Tanaka S, Tajima K, et al. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 2006;15:1315-1319.
101. Kuo SH, Chang DB, Lee YC, et al. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Respirology 1998;3:55-59.
102. Schutt P, Schutt B, Switala M, et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010;71:489-495.
103. Lin A, Zhu CC, Chen HX, et al. Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. J Cell Mol Med 2010;14:2318-2329.
104. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006;24:178-186.
105. Mami-Chouaib F, Echchakir H, Dorothee G, et al. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002;188:114-121. (Pubitemid 35398869)
106. Gobert M, Treilleux I, driss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-2009.
107. Steinman RM. The dendritic cell system and its role in immunogenic-ity. Annu Rev Immunol 1991;9:271-296.
108. Inoshima N, Nakanishi Y, Minami T, et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis ofnon-small cell lung cancer. Clin Cancer Res 2002;8: 3480-3486. (Pubitemid 35340725)
109. Dai F, Liu L, Che G, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010;10:220.
110. Yuan A, Steigen SE, Goll R, et al. Dendritic cell infiltration pattern along the colorectal adenoma-carcinoma sequence. APMIS 2008;116: 445-456.
111. Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293-301.
112. Coventry BJ, Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer 2003;89: 533-538. (Pubitemid 37026439)
113. Dumitriu IE, Dunbar DR, Howie SE, et al. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2009;182:2795-2807.
114. Li Q, Guo Z, Xu X, et al. Pulmonary stromal cells induce the generation of regulatory DC attenuating T-cell-mediated lung inflam-mation. Eur J Immunol 2008;38:2751-2761.
115. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008;112:863-875. (Pubitemid 351240580)
116. Esendagli G, Bruderek K, Goldmann T, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008;59:32-40.
117. Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35:23-28. (Pubitemid 34028087)
118. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Car-diovasc Surg 2001;121:1058-1063.
119. Hiraoka K, Zenmyo M, Watari K, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008;99:1595-1602.
120. Dundar E, Oner U, Peker BC, et al. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. JInt Med Res 2008;36:88-95. (Pubitemid 351255974)
121. Al-Shibli K, Al-Saad S, Andersen S, et al. The prognostic value of intraepithelial and stromal CD3-, CD117-and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010;118:371-382.
122. Tomita M, Matsuzaki Y, Onitsuka T. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 1999;26:103-108. (Pubitemid 29492898)
123. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88:2686-2692. (Pubitemid 30417928)
124. Lee TK, Horner RD, Silverman JF, et al. Morphometric and morpho-logic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer 1989;63:309-316. (Pubitemid 19035024)
125. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithe-lial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227.
126. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94:1003-1009. (Pubitemid 37521216)
127. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-280. (Pubitemid 43151547)
128. Pelletier MP, Edwardes MD, Michel RP, et al. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can JSurg 2001;44:180-188. (Pubitemid 32538769)
129. Nakamura H, Saji H, Ogata A, et al. Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 2002;37: 161-169. (Pubitemid 34831808)
130. Granville CA, Memmott RM, Balogh A, et al. A central role for Foxp3 + regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One 2009;4:e5061.
131. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3 + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-590.
132. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3 + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-2872. (Pubitemid 44937041)
133. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prosta-glandin E2-dependent promotion of FOXP3 expression and CD4+ CD25 + T regulatory cell activities in lung cancer. Cancer Res 2005; 65:5211-5220. (Pubitemid 40827331)
134. Donnem T, Al-Shibli K, Andersen S, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010;116:4318-4325.
135. Tormanen-Napankangas U, Soini Y, Paakko P. High number of tu-mour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS 2001;109:525-532. (Pubitemid 32844260)
136. Johnson SK, Kerr KM, Chapman AD, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000;27:27-35.
137. Venkataraman M, Rao DS, Iyer BS, et al. The functional deficiency of B lymphocytes in patients with lung cancer is due to inadequate T-cell help and excessive suppression by T and non-T cells. Cancer Invest 1989;7:7-16. (Pubitemid 19192621)
138. Saccani A, Schioppa T, Porta C, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 in-flammatory responses and antitumor resistance. Cancer Res 2006; 66:11432-11440. (Pubitemid 46009975)
139. Hagemann T, Lawrence T, McNeish I, et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. JExp Med 2008;205: 1261-1268. (Pubitemid 351831483)
140. Ruckdeschel JC, Codish SD, Stranahan A, et al. Postoperative empy-ema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl JMed 1972;287:1013-1017.
141. Baldwin RW, Pimm MV BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer 1973;27: 48-54.
142. McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976;1:377-379.
143. Van den Heuvel MM, Burgers SA, van ZN. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer 2009;10:99-105.
144. Kerr KM, Johnson SK, King G, et al. Partial regression in primary carcinoma of the lung: does it occur? Histopathology 1998;33:55-63. (Pubitemid 28352572)
145. ChoudhuryA, PalmaM, Mellstedt H. The future of cancervaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer 2008; 9(Suppl 1):S37-S44. (Pubitemid 351345726)
146. Ho C, Ochsenbein AF, Gautschi O, et al. Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008;9(Suppl 1):S20-S27. (Pubitemid 351345724)
147. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(Suppl 18):398.
148. Sangha R, Butts C L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13:s4652-s4654.
149. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681. (Pubitemid 46190262)